<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> are at increased risk of both thromboembolic and haemorrhagic complications </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0005305'>Cerebral thrombosis</z:hpo> is a common cause of <z:hpo ids='HP_0011420'>death</z:hpo> in <z:mpath ids='MPATH_512'>myeloproliferative disease</z:mpath> patients </plain></SENT>
<SENT sid="2" pm="."><plain>Picotamide is a new anti-platelet drug sharing a dual anti-<z:chebi fb="0" ids="26995">thromboxane</z:chebi> activity: inhibition of <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> synthase and <z:chebi fb="0" ids="15627">thromboxane A2</z:chebi> receptor antagonism </plain></SENT>
<SENT sid="3" pm="."><plain>Picotamide inhibits in vitro and ex vivo platelet aggregation induced by different <z:chebi fb="4" ids="48705">agonists</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, in vitro studies show that picotamide is able to increase prostacycline biosynthesis </plain></SENT>
<SENT sid="5" pm="."><plain>In the clinical setting, picotamide treatment induces only a slight prolongation of <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="6" pm="."><plain>The safety and efficacy of picotamide long-term treatment in 15 patients with essential <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> and a positive history of previous <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> was evaluated </plain></SENT>
<SENT sid="7" pm="."><plain>After 12-month treatment with picotamide no patients suffered from thrombotic events and only one minor and transient <z:mp ids='MP_0001914'>bleeding</z:mp> episode was observed </plain></SENT>
<SENT sid="8" pm="."><plain>This observational long-term trial shows that picotamide treatment in patients with <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> at high risk of thrombotic events is safe and well tolerated </plain></SENT>
<SENT sid="9" pm="."><plain>Picotamide did not increase the risk of <z:mp ids='MP_0001914'>bleeding</z:mp> in these patients, while at the same time, no thrombotic events were observed during the 1-year treatment </plain></SENT>
</text></document>